Track record · closed signal

Halozyme Therapeutics, Inc. (HALO) — closed signal from October 28, 2025

Partial Published before the outcome was known, scored automatically when the window closed on January 26, 2026.

Predicted vs. what happened

HALO price · publication thesis → realized outcomesplit-adjusted
$65.57 Published $80.00 Target $69.87 Window close $75.59 Peak
$64.50 – $66.50Entry zone — fair-value band
$65.57Published — price the day we called it
$80.00Target — the price the thesis aimed for
$75.59Peak — highest point inside the window, not a realized return
$69.87Window close — end-of-window price, context only

What happened

Partial

Reached 70% of the predicted growth at its peak, without hitting the target.

Peak price
$75.59
peak on January 7, 2026 — not a realized return
Peak gain
+15.3%
peak, from the publication price
Window close
$69.87
end-of-window price, context only
Days to target
—
Window
October 28, 2025 – January 26, 2026

The thesis — published October 28, 2025

Predicted growth
+22%
over the measurement window
Target price
$80.00
the price the thesis aimed for
Entry zone
$64.50 – $66.50
the fair-value band we waited for
Price at publication
$65.57
published October 28, 2025
Confidence
88%
how strongly the data lined up
Timeframe
Short-term (0–3 months)

Near-term setup looks attractive: more buyers are stepping in even as the recent average price trend remains soft, so aiming near the lower end before the Nov 3 earnings makes sense. Royalties from ENHANZE keep cash coming in, which could lift the stock over the next three months. Early signs suggest a possible earnings beat, and the Elektrofi deal adds delivery tech. Add more only if strength holds after results.

Primary drivers

  • Momentum shows more buyers than usual, leaving room for a rebound ahead
  • ENHANZE royalties offer steady income that can help smooth earnings
  • Earnings next week; early data hints the company could beat estimates
  • Elektrofi purchase adds new drug delivery options, widening the toolkit

How it played out

HALO: the thesis partly played out, but missed $80

Lyra published HALO at $65.57 on 2025-10-28, with a short-term view for 22% growth toward $80. The thesis pointed to more buyers stepping in, ENHANZE royalties, a possible earnings beat the next week, and the Elektrofi purchase adding drug delivery options.

Inside the 2025-10-28 to 2026-01-26 window, HALO rose but never reached $80. It peaked at $75.59 on 2026-01-07, a 15.3% gain, then ended the window at $69.87. The call caught part of the move, but the published target was missed.

What happened during the window

On November 12, 2025, Investor's Business Daily reported that Halozyme had posted better than expected third-quarter earnings on November 3. On December 18, 2025, Investor's Business Daily reported a Composite Rating upgrade from 94 to 96 and noted 35% earnings growth for Q3.

Prices are shown split- and dividend-adjusted, matching what public charts show today.

Share this receipt

A scored call, published before the outcome was known. Paste the link anywhere — it unfurls as the card above.

Lyra

Read the next call before it closes.

This is one signal, scored after the fact. Today’s picks come with the same plain-language thesis — published before anyone knows the outcome.

See today’s picks All HALO signals